Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Classical hematology 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Fanconi Anemia 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × prexasertib × Clear all
NCT06597565 2025-10-20

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
43 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡